Hye-Jin Jeong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hye-Jin Jeong has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Joo H. Kang
Department of Biomedical Engineering Ulsan National Institute of Science and Technology (UNIST) Ulsan Republic of Korea
21 shared publications - Tae-Eun Park
Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, Ulsan, Korea
21 shared publications - Chang Sik Yu
Division of Colon and Rectal Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
20 shared publications - Dayoung Kim
Ulsan National Institute of Science and Technology, Korea (South), Republic of
20 shared publications - Deok-Beom Jung
Asan Medical Center, Seoul, Korea (South), Republic of
20 shared publications - Euihwan Jeong
Cascure Therapeutics, Korea (South), Republic of
20 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Table S4 provides information on the putative off-target sites of each sgRNA in Hmix-4, as identified by Cas-Offinder and CRISPOR analyses.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Table S4 provides information on the putative off-target sites of each sgRNA in Hmix-4, as identified by Cas-Offinder and CRISPOR analyses.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S14 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S14 shows quantitative measurements of BRCA2 expression upon siRNA or shRNA-mediated knock-down, and verifies the synthetic lethality of PARP inhibition in BRCA2-deficient cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S14 shows quantitative measurements of BRCA2 expression upon siRNA or shRNA-mediated knock-down, and verifies the synthetic lethality of PARP inhibition in BRCA2-deficient cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S4 evaluates the specificity and safety of multiplexed CRISPR-induced cytotoxicity by examining its effects on non-target loci and various cell lines.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S4 evaluates the specificity and safety of multiplexed CRISPR-induced cytotoxicity by examining its effects on non-target loci and various cell lines.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S10 evaluates the in vivo antitumor effects of sgRNA-loaded liposomes in a mouse xenograft model using HCT-116 cells stably expressing Cas9 nucleases.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S10 evaluates the in vivo antitumor effects of sgRNA-loaded liposomes in a mouse xenograft model using HCT-116 cells stably expressing Cas9 nucleases.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S6 illustrates how predicted SpCas9 activity and CRISPR-induced mutation patterns affect the efficiency of cell death following multiplexed CRISPR targeting.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S6 illustrates how predicted SpCas9 activity and CRISPR-induced mutation patterns affect the efficiency of cell death following multiplexed CRISPR targeting.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S13 demonstrates the inhibitory role of olaparib in the repair of DNA single-strand breaks induced by multiplexed CRISPR/nCas9D10A.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S13 demonstrates the inhibitory role of olaparib in the repair of DNA single-strand breaks induced by multiplexed CRISPR/nCas9D10A.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S2 presents representative images demonstrating the effect of RNP- or RNA-based delivery of multiplexed CRISPR/Cas systems on cell viability in various cancer cell lines.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S2 presents representative images demonstrating the effect of RNP- or RNA-based delivery of multiplexed CRISPR/Cas systems on cell viability in various cancer cell lines.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S9 provides high-resolution whole-slide immunohistochemical images of HCT-116 xenograft tumors treated with either PBS or multiplexed CRISPR/Cas9WT RNP-loaded LNPs.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S9 provides high-resolution whole-slide immunohistochemical images of HCT-116 xenograft tumors treated with either PBS or multiplexed CRISPR/Cas9WT RNP-loaded LNPs.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S7 presents bright-field images showing that multiplexed sgRNAs targeting proximal sites near the C4BPB gene do not induce cytotoxic effects.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S7 presents bright-field images showing that multiplexed sgRNAs targeting proximal sites near the C4BPB gene do not induce cytotoxic effects.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S5 shows the genomic context of four intergenic sgRNAs that effectively induced cell death, demonstrating that CRISPR-induced cytotoxicity can occur independently of gene function.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S5 shows the genomic context of four intergenic sgRNAs that effectively induced cell death, demonstrating that CRISPR-induced cytotoxicity can occur independently of gene function.